CalciMedica, Inc.
CALC · NASDAQ
Market closed$0.735600$0.041600 (+5.99%)After hours $0.790000 · +7.40%
Key statistics
Previous close$0.694000
Open$0.733900
Day high$0.769800
Day low$0.700000
52-week high$7.20
52-week low$0.461000
Market cap11.62M
Volume194.70K
Average volume1.28M
P/E ratio-0.55
Forward P/E—
EPS-1.33
Dividend yield0.00%
Market context
Why it moved
CALC shares rose sharply, likely driven by positive investor sentiment and speculative buying interest in the small-cap biotech space, potentially as investors rotated into value and smaller healthcare names amid the broader tech and semiconductor selloff triggered by China's Kimi K3 AI model announcement.
What is happening
Recent company-specific developments and publisher coverage.
TradingView · July 10, 2026Alafi Capital Discloses Investment at CalciMedica with 17.1% StakeTradingView · July 3, 2026Bering Partners II Discloses Investment at CalciMedica with 6.9% StakeMoomoo · June 24, 2026CalciMedica Entered Into Definitive Securities Purchase Agreement With Leading Healthcare Investors >CALCStock Titan · June 24, 2026FDA gives CalciMedica no comments on Auxora safety reviewPR Newswire · June 24, 2026CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension ProgramBenzinga · June 24, 2026What's Going On With CalciMedica Stock Wednesday? - CalciMedica (NASDAQ:CALC)PR Newswire · May 12, 2026CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesClinical Trials Arena · January 29, 2026CalciMedica’s stock drops 75% on acute kidney injury trial termination Benzinga · June 24, 2026FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial Benzinga · June 24, 2026CalciMedica Announces Private Placement Worth Up To ~$49M In Gross Proceeds Benzinga · June 24, 2026CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora Benzinga · May 12, 2026CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate Benzinga · March 5, 2026Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10 Mt Newswire · March 5, 2026Oppenheimer Adjusts CalciMedica Price Target to $10 From $20, Maintains Outperform Rating Benzinga · March 3, 2026CalciMedica Q4 EPS $(0.69) Misses $(0.42) Estimate Mt Newswire · January 29, 2026HC Wainwright Downgrades CalciMedica to Neutral From Buy